Table 2 Non-inferiority of SII-NVX-CoV2373 heterologous booster to homologous booster in terms for Anti-S IgG and neutralizing antibodies at Visit 2-Day 29 - Per Protocol Population.
ChAdOx1 nCoV-19 Prime Cohort | BBV152 prime cohort | |||
|---|---|---|---|---|
SII-NVX-CoV2373 (N = 92) | ChAdOx1 nCoV-19 (N = 93) | SII-NVX-CoV2373 (N = 91) | BBV152 (N = 93) | |
Anti-S IgG | ||||
GMEU [1] with 95% CI | 65,550.37 (58,155.85, 73,885.11) | 31,945.42 (28,366.25, 35,976.20) | 65,155.31 (56,348.14, 75,339.04) | 12,719.72 (11,063.37, 14,624.05) |
GMEU Ratio (GMR) [1] with 95% CI | 2.05 (1.73, 2.43) | 5.12 (4.20, 6.24) | ||
Seroresponse | ||||
n (%) 95% CI | 80 (86.96) (78.32, 93.07) | 35 (37.63) (27.79, 48.28) | 86 (94.51) (87.64, 98.19) | 19 (20.43) (12.77, 30.05) |
Difference in Proportions 95% CI | 49.32 (36.49, 60.45) | 74.08 (63.24, 82.17) | ||
Neutralizing antibodies | ||||
GMT [1] 95% Confidence Interval | 3883.22 (3363.26, 4483.56) | 2050.29 (1777.55, 2364.88) | 2654.90 (2221.75, 3172.49) | 553.59 (466.46, 657.00) |
GMT Ratio (GMR) [1] 95% Confidence Interval | 1.89 (1.55, 2.32) | 4.80 (3.76, 6.12) | ||
Seroresponse | ||||
n (%) 95% CI | 87 (94.57) (87.77, 98.21) | 74 (79.57) (69.95, 87.23) | 90 (98.90) (94.03, 99.97) | 69 (74.19) (64.08, 82.71) |
Difference in Proportions 95% CI | 15.00 (5.65, 25.05) | 24.71 (16.26, 34.62) | ||
